Literature DB >> 8412020

Inborn errors and demyelination: MRI and the diagnosis of white matter disease.

B E Kendall1.   

Abstract

The progress and extent of myelination can be assessed using magnetic resonance imaging (MRI). Myelination is delayed or diminished in several inherited metabolic abnormalities presenting in early life. Only minimal myelination of the CNS occurs in Pelizaeus-Merzbacher disease. Dysmyelination tends to produce fairly symmetrical lesions affecting white matter. In many mitochondrial enzyme and some lysosomal defects, the grey matter is also involved. The appearances and in particular the distribution on MRI and/or CT are characteristic in some conditions and the diagnosis is limited in others. Demyelination due to inflammatory disorders typically causes multifocal white matter lesions, recurrent in multiple sclerosis, monophasic in acute disseminated encephalomyelitis, extending in progressive multifocal leukoencephalopathy and classically involving the pons or corpus callosum in myelinolysis. Hypoxic ischaemic lesions may be metabolically induced and simulate primary demyelinating disorders. Mitochondrial enzyme defects in particular may present with stroke-like appearances. In many of these conditions, diagnosis is biochemical, but imaging has a significant role in suggesting the diagnosis, and documenting progression, response to therapy or complications.

Entities:  

Mesh:

Year:  1993        PMID: 8412020     DOI: 10.1007/bf00711909

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  7 in total

1.  Tay-Sachs disease: progression of changes on neuroimaging in four cases.

Authors:  M Fukumizu; H Yoshikawa; S Takashima; N Sakuragawa; T Kurokawa
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

2.  Marchiafava-Bignami disease: serial changes in corpus callosum on MRI.

Authors:  K H Chang; S H Cha; M H Han; S H Park; D L Nah; J H Hong
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

Review 3.  Disorders of lysosomes, peroxisomes, and mitochondria.

Authors:  B E Kendall
Journal:  AJNR Am J Neuroradiol       Date:  1992 Mar-Apr       Impact factor: 3.825

4.  Cranial CT and MRI in diseases with DNA repair defects.

Authors:  P Demaerel; B E Kendall; D Kingsley
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

5.  Computed tomography in Alexander's disease. An atypical case with extensive low density in both frontal lobes.

Authors:  A G Clifton; B E Kendall; D P Kingsley; J H Cross; U Andar
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

6.  Partial albinism with immunodeficiency: a rare syndrome with prominent posterior fossa white matter changes.

Authors:  J Brismar; H A Harfi
Journal:  AJNR Am J Neuroradiol       Date:  1992 Jan-Feb       Impact factor: 3.825

7.  Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis.

Authors:  J Kesselring; D H Miller; S A Robb; B E Kendall; I F Moseley; D Kingsley; E P du Boulay; W I McDonald
Journal:  Brain       Date:  1990-04       Impact factor: 13.501

  7 in total
  5 in total

1.  Neuroimaging in chronic fatigue syndrome.

Authors:  H Cope; A S David
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

Review 2.  Diffusion-weighted MR imaging in leukodystrophies.

Authors:  Zoltan Patay
Journal:  Eur Radiol       Date:  2005-07-15       Impact factor: 5.315

Review 3.  The inherited leukodystrophies: a clinical overview.

Authors:  J Aicardi
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

4.  Corpus callosum signal intensity in patients with bipolar and unipolar disorder.

Authors:  P Brambilla; M Nicoletti; R B Sassi; A G Mallinger; E Frank; M S Keshavan; J C Soares
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

5.  Pelizaeus-merzbacher disease: the first genetically approved case report from iran.

Authors:  Mahmoud-Reza Ashrafi; Mahmoud Mohammadi; Hooman Alizadeh; Ali Nikkhah
Journal:  Iran J Pediatr       Date:  2011-09       Impact factor: 0.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.